Surveillance for West Nile Virus Disease - United States, 2009-2018.
Journal
Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)
ISSN: 1545-8636
Titre abrégé: MMWR Surveill Summ
Pays: United States
ID NLM: 101142015
Informations de publication
Date de publication:
05 03 2021
05 03 2021
Historique:
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
19
3
2021
Statut:
epublish
Résumé
West Nile virus (WNV) is an arthropodborne virus (arbovirus) in the family Flaviviridae and is the leading cause of domestically acquired arboviral disease in the contiguous United States. An estimated 70%-80% of WNV infections are asymptomatic. Symptomatic persons usually develop an acute systemic febrile illness. Less than 1% of infected persons develop neuroinvasive disease, which typically presents as encephalitis, meningitis, or acute flaccid paralysis. 2009-2018. WNV disease is a nationally notifiable condition with standard surveillance case definitions. State health departments report WNV cases to CDC through ArboNET, an electronic passive surveillance system. Variables collected include patient age, sex, race, ethnicity, county and state of residence, date of illness onset, clinical syndrome, hospitalization, and death. During 2009-2018, a total of 21,869 confirmed or probable cases of WNV disease, including 12,835 (59%) WNV neuroinvasive disease cases, were reported to CDC from all 50 states, the District of Columbia, and Puerto Rico. A total of 89% of all WNV patients had illness onset during July-September. Neuroinvasive disease incidence and case-fatalities increased with increasing age, with the highest incidence (1.22 cases per 100,000 population) occurring among persons aged ≥70 years. Among neuroinvasive cases, hospitalization rates were >85% in all age groups but were highest among patients aged ≥70 years (98%). The national incidence of WNV neuroinvasive disease peaked in 2012 (0.92 cases per 100,000 population). Although national incidence was relatively stable during 2013-2018 (average annual incidence: 0.44; range: 0.40-0.51), state level incidence varied from year to year. During 2009-2018, the highest average annual incidence of neuroinvasive disease occurred in North Dakota (3.16 cases per 100,000 population), South Dakota (3.06), Nebraska (1.95), and Mississippi (1.17), and the largest number of total cases occurred in California (2,819), Texas (2,043), Illinois (728), and Arizona (632). Six counties located within the four states with the highest case counts accounted for 23% of all neuroinvasive disease cases nationally. Despite the recent stability in annual national incidence of neuroinvasive disease, peaks in activity were reported in different years for different regions of the country. Variations in vectors, avian amplifying hosts, human activity, and environmental factors make it difficult to predict future WNV disease incidence and outbreak locations. WNV disease surveillance is important for detecting and monitoring seasonal epidemics and for identifying persons at increased risk for severe disease. Surveillance data can be used to inform prevention and control activities. Health care providers should consider WNV infection in the differential diagnosis of aseptic meningitis and encephalitis, obtain appropriate specimens for testing, and promptly report cases to public health authorities. Public health education programs should focus prevention messaging on older persons, because they are at increased risk for severe neurologic disease and death. In the absence of a human vaccine, WNV disease prevention depends on community-level mosquito control and household and personal protective measures. Understanding the geographic distribution of cases, particularly at the county level, appears to provide the best opportunity for directing finite resources toward effective prevention and control activities. Additional work to further develop and improve predictive models that can foreshadow areas most likely to be impacted in a given year by WNV outbreaks could allow for proactive targeting of interventions and ultimately lowering of WNV disease morbidity and mortality.
Identifiants
pubmed: 33661868
doi: 10.15585/mmwr.ss7001a1
pmc: PMC7949089
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-15Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Références
Rev Med Virol. 2006 Jul-Aug;16(4):209-24
pubmed: 16906589
MMWR Recomm Rep. 1997 May 2;46(RR-10):1-55
pubmed: 9148133
Lancet Infect Dis. 2002 Sep;2(9):519-29
pubmed: 12206968
J Infect Dis. 1999 Jan;179(1):230-3
pubmed: 9841844
Emerg Infect Dis. 2005 Aug;11(8):1174-9
pubmed: 16102303
Emerg Infect Dis. 2013 Nov;19(11):1836-8
pubmed: 24210089
Clin Infect Dis. 2006 May 1;42(9):1234-40
pubmed: 16586381
MMWR Morb Mortal Wkly Rep. 2001 Jan 26;50(3):37-9
pubmed: 11215880
Lancet. 1998 Sep 5;352(9130):767-71
pubmed: 9737281
Emerg Infect Dis. 2005 Aug;11(8):1167-73
pubmed: 16102302
MMWR Surveill Summ. 2010 Apr 2;59(2):1-17
pubmed: 20360671
Am J Trop Med Hyg. 1955 Sep;4(5):872-88
pubmed: 13259011
Vector Borne Zoonotic Dis. 2004 Spring;4(1):61-70
pubmed: 15018774
Vector Borne Zoonotic Dis. 2008 Spring;8(1):35-9
pubmed: 18237264
Ann Intern Med. 2004 Sep 7;141(5):360-5
pubmed: 15353427
Emerg Infect Dis. 2001 Jan-Feb;7(1):128-32
pubmed: 11266303
J Med Entomol. 2005 Jan;42(1):57-62
pubmed: 15691009
JAMA. 2013 Jul 17;310(3):308-15
pubmed: 23860989
Clin Vaccine Immunol. 2007 Sep;14(9):1084-93
pubmed: 17609393
Transplantation. 2004 Feb 15;77(3):399-402
pubmed: 14966414
Vector Borne Zoonotic Dis. 2007 Winter;7(4):479-88
pubmed: 17979539
Emerg Infect Dis. 2006 Jul;12(7):1129-31
pubmed: 16836833
Emerg Infect Dis. 2001 Jul-Aug;7(4):621-5
pubmed: 11585522
Vector Borne Zoonotic Dis. 2005 Fall;5(3):246-51
pubmed: 16187893
N Engl J Med. 2001 Jun 14;344(24):1807-14
pubmed: 11407341
J Infect Dis. 2010 Nov 1;202(9):1354-61
pubmed: 20874087
J Clin Microbiol. 2000 May;38(5):1823-6
pubmed: 10790107
Epidemiol Infect. 2013 Mar;141(3):591-5
pubmed: 22640592
MMWR Recomm Rep. 1990 Oct 19;39(RR-13):1-43
pubmed: 2122225
Emerg Infect Dis. 2007 Dec;13(12):1918-20
pubmed: 18258047
Lancet. 2001 Jul 28;358(9278):261-4
pubmed: 11498211
Epidemiol Infect. 2006 Dec;134(6):1325-32
pubmed: 16672108